Loading clinical trials...

Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III | Clinical Trials | Clareo Health

TERMINATED

Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III

Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Patients 1 Year of Age and Over With GSD III

NCT05196165•Ultragenyx Pharmaceutical Inc

View on ClinicalTrials.gov

Summary

The primary objective of this study is to evaluate the incidence of hypoglycemia in adult and pediatric participants with glycogen storage disease type III (GSD III).

Eligibility

Age

1 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of GSD III, confirmed by amylo-alpha-1,6-glucosidase 4-alpha-glucanotransferase (AGL) sequencing or glycogen debranching enzyme (GDE) enzymatic testing

Exclusion Criteria

•Participant is unwilling to remain blinded to continuous glucose monitor (CGM) data for the first 13 weeks of the study, or the Investigator determines that blinding would compromise subject safety
•Presence or history of any condition that, in the view of the Investigator, would interfere with participation or pose undue risk
•Use of any IP or investigational medical device within 30 days or 5.5 half-lives, whichever is longer, prior to screening, or during the study
•Note: Other criteria may apply per protocol

Locations (4)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Baylor College of Medicine

Houston, Texas, United States

University of Texas

Houston, Texas, United States

University of Groningen Beatrix Children's Hospital

Groningen, Netherlands

Key Dates

Start Date

May 20, 2022

Primary Completion Date

March 2, 2023

Completion Date

March 2, 2023

Last Updated

September 28, 2023

Enrollment

ACTUAL participants

Conditions

Glycogen Storage Disease Type III

Interventions

No Intervention

OTHER

French Observatory for Patients with Type 3 Glycogenosis

NCT06616545

Glycogen Storage Disease Type III

View study

TERMINATEDPHASE1/PHASE2

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

NCT04990388

Glycogen Storage Disease Type III

View study

COMPLETEDNA

Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies

NCT02448667

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 28, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions